Drug Trial Radar · NCT01555463
Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea
Last checked: Nov 19, 2026Latest source record: Jun 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
961
Actual
Start
Sep 2012
Primary completion
Jan 2014
Study completion Jan 2014
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Mar 15, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of azelaic acid (AzA) foam, 15% topically applied twice daily for 12 weeks in subjects with papulopustular rosacea compared to its vehicle.
Conditions
- Papulopustular Rosacea
Interventions
Azelaic acid foam, 15% (BAY39-6251)Drug
Azelaic acid twice daily topical application
Vehicle foamDrug
twice daily topical application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward)Time frame: At end of treatment (LOCF), up to 12 weeks
- Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF)Time frame: Baseline and end of treatment (LOCF), up to 12 weeks
Locations
49 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Fremont, California
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Santa Ana, California
Site not named
Santa Monica, California
Site not named
Colorado Springs, Colorado
Site not named
Boynton Beach, Florida
Site not named
Boynton Beach, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Miramar, Florida
Site not named
Ormond Beach, Florida
Site not named
Saint Augustine, Florida
Site not named
Buffalo Grove, Illinois
Site not named
Chicago, Illinois
Site not named
Plainfield, Indiana
Site not named
Louisville, Kentucky
Site not named
Richmond, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Warren, Michigan
Site not named
West Bloomfield, Michigan
Site not named
Fridley, Minnesota
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Las Vegas, Nevada
Site not named
East Windsor, New Jersey
Site not named
New York, New York
Site not named
Stony Brook, New York
Site not named
Chapel Hill, North Carolina
Site not named
Hickory, North Carolina
Site not named
High Point, North Carolina
Site not named
Raleigh, North Carolina
Site not named
Winston-Salem, North Carolina
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.